Zhongrong Trust helps push production integration and upgrade

Recently, Changguanghua Medical, Zhongrong Trust participated in investment, announced the completion of 100 million yuan Pre-IPO round financing. With the supply chain of upstream raw materials, the concept of advanced quality management system, and the price advantage of localized production, it is expected to be ranked among the top chemical lighting enterprises in the domestic first echelon in the future.

Based on the rapid development of the IVD industry in China, after fully demonstrating the business model and core competitiveness of Changguanghua Medicine, Beijing Zhongrong Dingxin Investment Management Co., Ltd. (hereinafter referred to as "Zhongrong Dingxin"), a subsidiary of Zhongrong Trust, to play He comprehensive financial advantages, layout "hard technology", fully participate in Changguanghua Medical equity financing, invest 100 million yuan in own funds, in order to promote the continuous improvement of Guanghua Medicine to continue to improve product research and development capabilities and brand influence, accelerate my country's IVD product realization of import substitution replacement Process.

Helping the development of biotechnology is also another innovative example of the principle of integration of production and finance and financial services. In recent years, Zhongrong Trust has continued to adjust and optimizes business structure, focusing on the development of new infrastructure construction, traditional industrial transformation and upgrading, and emerging industry investment support. In the cooperation, Zhongrong Trust pays more attention to the common growth of the enterprise. Not only does it pay attention to the short -term financial return, but also hopes to provide customized financial services for enterprise development by giving play to its own financial institutions' advantages and resource integration capabilities to provide customized financial services for enterprise development. Growth and development contribute value. As of now, the company has provided comprehensive financial services for thousands of companies, which has effectively helped industrial upgrading and emerging industries.

Zhongrong Dingxin was formally approved by the original China Banking Regulatory Commission in 2011. As a wholly -owned subsidiary and an equity investment platform of Zhongrong Trust, through 11 years of development, the total scale of Zhongrong Dingxin and subsidiaries has exceeded 32.2 billion yuan, the total scale of trustee assets exceeds 21 billion yuan, and more than 60 funds have been picked up. The company gives full play to the asset management capabilities, continuously capture new investment opportunities, and extensively participate in the form of contract -type funds, limited partnership funds and other forms, and extensively participate in government industrial funds, capital market mergers and acquisitions, reorganization, targeted issuance, investment and financing of listed companies, equity of non -listed companies, equity of non -listed companies Investment, asset disposal and other business opportunities have participated in Focus Media, Mango Super Media, Huada Gene, Tianfeng Securities, China Gold, Fudan Microelectronics, Xinke Mobile and other well -known companies before listing, as well as QQ music and Lanqi Famous projects such as science and technology equity trading.

Changguanghua Medical was created by the Institute of Suzhou Biomedical Engineering Technology of the Chinese Academy of Sciences, the Changchun Optical Precision Machinery and Physics Research Institute and Mr. Dong Jianhua of the Chinese Academy of Sciences. Supporting reagents, as well as the first domestic automatic blood type analyzer suitable for micro -column gel immune detection technology. Reagent products cover tumor logo, infectious diseases, thyroid, inflammation, myocardial logo, eugenics, liver fibrosis, etc. 315 authorized patents have been obtained (including 74 invention authorization patents). Obtain 105 medical device registration certificates, three of which 35 registered certificates.

At the end of 2018, French Bio Merry (hereinafter referred to as "Merrier") became the controlling shareholder of Changguanghua Medical. Founded in 1963, Merrier relied on its own technological innovation and industrial production resources. It has always been committed to research and development as medical and industrial use in vitro diagnostic products. Merrier has branches, research and development centers, and manufacturing plants in 150 countries and regions in the world. The business spreads in six continents in the world, with about 9,800 employees worldwide. After completing the acquisition of Changguanghua Medicine, Merrier began an all -round improvement from R & D to production, market to sales.

(CIS)

- END -